According to Avadel Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $27.96 M. In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $27.96 M | |
2022 | N/A | |
2021 | N/A | -100% |
2020 | $22.33 M | -62.28% |
2019 | $59.21 M | -42.66% |
2018 | $0.10 B | -40.39% |
2017 | $0.17 B | 15.31% |
2016 | $0.15 B | -12.65% |
2015 | $0.17 B | 2581.77% |
2014 | $6.41 M | -71.42% |
2013 | $22.44 M | -14.01% |
2012 | $26.1 M | -19.94% |
2011 | $32.6 M | -12.12% |
2010 | $37.09 M | -11.93% |
2009 | $42.11 M | 9.06% |
2008 | $38.61 M | 5.36% |
2007 | $36.65 M | 59.23% |
2006 | $23.02 M | -2.45% |
2005 | $23.59 M | -65.68% |
2004 | $68.75 M | 177.25% |
2003 | $24.8 M | 35.07% |
2002 | $18.36 M | 40.3% |
2001 | $13.08 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | $0.86 B | 2,987.99% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $0.22 M | -99.19% | ๐บ๐ธ USA |